Focal treatment with Ablatherm® HIFU
The typical prostate cancer patient has evolved over the past 20 years ineluctably leading to new therapeutic needs. In the 1990s, the life expectancy for the patient diagnosed with prostate cancer rounded 7 years; therefore the need for aggressive curative (radical prostatectomy and radiation therapy) treatments was strong despite the impact on quality of life.
As of today, patients are diagnosed at earlier stages and at a younger age, often in their early 60s, with a life expectancy of 15 years. Offering them the same treatment options as 20 years ago dramatically jeopardizes their quality of life which is now their major concern.
Ablatherm® HIFU is a modern, truly non-invasive, focal treatment guaranteeing to preserve patients’ quality of life and leaving all treatment options open including repeat HIFU in case of local recurrence of the disease.
Focal treatment for localized prostate cancer is an answer to limiting the treatment to the prostatic area affected by cancer to reduce side effects such as incontinence and erectile dysfunction. Ablatherm HIFU is designed to do custom treatment depending on each patient’s prostate anatomy and is therefore perfectly suited for focal treatment.
For Ablatherm HIFU, focal treatment is divided into several protocols:
- Prostate hemi-ablation: treatment of the half of the prostate affected by cancer
- Nerve-sparing: treatment intended to maintain erectile function by treating the whole prostate except the neurovascular bundles on each side of the prostate
- Zonal treatment: the most cancer-targeted approach treating only the area affected by cancer
Preserving quality of life with focal Ablatherm HIFU treatment
- Erection nerves are not treated enabling to maintain erections (unilaterally or bilaterally)
- Urinary continence structures are preserved
Currently, there are more than 25 renowned European hospitals doing one or more of the focal Ablatherm® HIFU focal approaches.
On-going clinical trial
In France, a hemi-ablation (treating only the half of the prostate affected by cancer) clinical trial supported by the French Association of Urology (AFU) is on-going in 15 hospitals. The main inclusion criteria are:
- Patients aged over 50
- T1c – T2a localized prostate cancer
- PSA level inferior to 10ng/ml
- Cancer limited to a single lobe
- Gleason score ≤ 6
For further information on the trial, click here.